Kazia presents GDC-0084 at EANO
(WorldNews Health)

ASX RELEASE 20 September 2019 GDC-0084 PHASE II STUDY IN GLIOBLASTOMA PRESENTED AT EANO CONFERENCE; PROGRESS UPDATE AND OUTLOOK FOR GDC-0084 PROGRAM Sydney, 20 September 2019 - Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide investors with a poster presentation concerning its ongoing phase II study of GDC-0084 in glioblastoma. The poster will be presented at the 14th Annual Meeting of the European Association of Neuro- Oncology (EANO), which is being held in Lyon, France from 19-22 September 2019. The poster will be presented by Professor Patrick Wen from Dana-Farber Cancer Institute, and Dr Jeremy Simpson from...